PDS Biotechnology Corporation reported its financial results for the third quarter of 2025, revealing a net loss of $9.0 million, a decrease from a loss of $10.7 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $26.9 million, compared to $29.7 million for the same period in 2024. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $4.6 million for the quarter, down from $6.8 million in the prior year, primarily due to lower manufacturing and clinical trial costs.
Total operating expenses for the third quarter were $8.1 million, down 20% from $10.2 million in the previous year. The company’s general and administrative expenses increased slightly to $3.6 million, up from $3.4 million, driven by higher professional fees. PDS Biotech's cash and cash equivalents stood at $26.2 million as of September 30, 2025, a decrease from $41.7 million at the end of 2024, reflecting ongoing operational expenditures and financing activities.
In terms of strategic developments, PDS Biotech has been active in advancing its clinical pipeline. The company initiated the VERSATILE-003 Phase 3 clinical trial for PDS0101 (Versamune® HPV) in March 2025 and reported positive results from the colorectal cancer cohort of a Phase 2 trial with PDS01ADC in July 2025. Additionally, the company has entered into various financing agreements, including a securities purchase agreement in April 2025 that raised approximately $20 million, which was used to retire previous debt.
Operationally, PDS Biotech has focused on expanding its clinical trials and product development. The company has not generated any revenue from product sales and does not expect to do so in the near future. It continues to rely on equity and debt financing to fund its operations, with plans to pursue additional capital through various means, including potential collaborations and government funding programs. However, the company has expressed concerns about its ability to continue as a going concern, citing substantial doubt about its financial viability over the next 12 months without securing additional funding.
Looking ahead, PDS Biotech anticipates that its research and development expenses will increase as it advances its clinical candidates through trials and seeks regulatory approvals. The company remains focused on its immunotherapy platforms, including Versamune® and PDS01ADC, and aims to address the challenges of current immunotherapy approaches. The ongoing clinical trials and strategic partnerships will be critical in determining the company's future financial performance and operational success.
About PDS Biotechnology Corp
PDS Biotechnology develops innovative immunotherapies targeting cancer and infectious diseases. Its core platform, Versamune, stimulates potent, tumor-specific T cell responses with a favorable safety profile. The company focuses on cancer treatments, including HPV-related and resistant cancers, and vaccines for infectious diseases like influenza. Its business model combines proprietary immunotherapy platforms with strategic collaborations to advance targeted, immune-based therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.